Skip to main content

Data checks

 


ChEMBL contains a broad range of binding, functional and ADMET type assays in formats ranging from in vitro single protein assays to anti proliferative cell-based assays. Some variation is expected, even for very similar assays, since these are often performed by different groups and institutes. ChEMBL includes references for all bioactivity values so that full assay details can be reviewed if needed, however there are a number of other data checks that can be used to identify potentially problematic results.

1) Data validity comments:

The data validity column was first included in ChEMBL v15 and flags activities with potential validity issues such as a non-standard unit for type or activities outside of the expected range. Users can review flagged activities and decide how these should be handled. The data validity column can be viewed on the interface (click 'Show/Hide columns' and select 'data validity comments') and can be found in the activities table in the full database.

* Acceptable ranges/units for standard_types are provided in the ACTIVITY_STDS_LOOKUP table. An exception is made for certain fragment-based activities (MW <= 350) where the data validity comment is not applied.

2) Confidence scores:

The confidence scores reflect both the target type and the confidence that the mapped target is correct (e.g. score 0 = no target assigned, score 9 = direct single protein target assigned). In cases where target protein accessions were unavailable during initial mapping, homologues from different species/strains have sometimes been assigned with lower confidence scores. Curation is ongoing and confidence scores may change between releases as additional assays are mapped (or re-mapped) to targets. The confidence scores can be viewed on the interface and are found in the assays table in the database.


3) Activity comments:

Activity comments capture the author or depositor’s overall activity conclusions and may take into account counter screens, curve fitting etc. It may be worth reviewing the activity comments to identify cases where apparently potent compounds have been deemed inactive by depositors. For further details on activity comments, see our previous Blog post. The activity comments can be viewed on the interface and are available in the activities table of the database.

4) Potential duplicates:

Bioactivity data is extracted from seven core journals and this may include secondary citations. Potential duplicates are flagged when identical compound, target, activity, type and unit values are reported. The potential duplicates field is available on the interface and is found in the activities table of the database.

5) Variants:

Protein variation can change the affinity of drugs for targets. On the interface, variant proteins are recorded in the assay descriptions which can be used to check whether activities correspond to variant or 'wild-type' targets. The variant sequences table was added to the database in version 22 and is linked to the assays table through the variant ID. The variant ID can be used to include or exclude variants from assay results. Curation is underway to annotate additional variants from historical assays (more on this to follow).

Hopefully this provides an idea of some of the available data checks. Questions? Please get in touch on the Helpdesk or have a look through our training materials and FAQs.

Data checks using Imatinib as an example:










Comments

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f